Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Aardvark Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Aardvark Therapeutics, Inc.’s stock price such as:

• Aardvark Therapeutics, Inc.’s current stock price and volume
• Why Aardvark Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for AARD from analysts
• AARD’s stock price momentum as measured by its relative strength

About Aardvark Therapeutics, Inc. (AARD)

Before we jump into Aardvark Therapeutics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen, which is in the Phase 3 clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in the Phase 2 clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from the treatment of craniopharyngioma, including surgery or radiation. The company is also developing ARD-201, which is in the Phase 1 clinical trial for the treatment of obesity. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Want to learn more about Aardvark Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Aardvark Therapeutics, Inc..

Aardvark Therapeutics, Inc.’s Stock Price as of Market Close

As of December 12, 2025, 4:00 PM, CST, Aardvark Therapeutics, Inc.’s stock price was $14.430.

Aardvark Therapeutics, Inc. is down 7.56% from its previous closing price of $15.610.

During the last market session, Aardvark Therapeutics, Inc.’s stock traded between $14.265 and $15.970. Currently, there are approximately 21.71 million shares outstanding for Aardvark Therapeutics, Inc..

Aardvark Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Aardvark Therapeutics, Inc. Stock Price History

Aardvark Therapeutics, Inc.’s (AARD) price is currently up 44.59% so far this month.

During the month of December, Aardvark Therapeutics, Inc.’s stock price has reached a high of $16.000 and a low of $9.180.

Over the last year, Aardvark Therapeutics, Inc. has hit prices as high as $19.580 and as low as $4.880.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Aardvark Therapeutics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of December 12, 2025, there was 1 analyst who downgraded Aardvark Therapeutics, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Aardvark Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Aardvark Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Aardvark Therapeutics, Inc. (AARD) by visiting AAII Stock Evaluator.

Relative Price Strength of Aardvark Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of December 12, 2025, Aardvark Therapeutics, Inc. has a weighted four-quarter relative price strength of %, which translates to a Momentum Score of and is considered to be NA.

Want to learn more about how Aardvark Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Aardvark Therapeutics, Inc. Stock Price: Bottom Line

As of December 12, 2025, Aardvark Therapeutics, Inc.’s stock price is $14.430, which is down 7.56% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Aardvark Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.